Efficacy Results - Avmapki™ Fakzynja™ Co-Pack HCP

This site is intended for US healthcare professionals.

Full Prescribing Information | Patient Site | Connect With A Rep Email Sign Up
Full Prescribing Information Patient Site Connect With A Rep Email Sign-Up
Illustration of a patient speaking with a healthcare professional in a clinic

REIMAGINE
The potential of a response

Clinical trial data support Avmapki Fakzynja Co‑Pack as a potential standard of care for adults with KRAS-mutated recurrent LGSOC1*

Avmapki Fakzynja Co‑Pack produced clinically meaningful response rates and DOR, with adverse events that were manageable in most patients.1

Efficacy was evaluated in RAMP-201:
an open-label, multicenter study2

Study Endpoints

• Efficacy was primarily determined by ORR as assessed by BIRC2
• Secondary endpoints included DoR, safety, and pharmacokinetics1

Patient population2

Adult patients with measurable KRAS-mutated recurrent LGSOC N=57
Median age, years (range) 60 (range 29-87)
Race and ethnicity (% of patients)
  • White, 75%
  • Asian, 3.5%
  • Hispanic or Latino, 3.5%
  • Black or African American, 3.5%
  • Not reported, 18%
Required ≥1 prior systemic therapy, including a platinum-based regimen (lines received, % of patients)
  • 1 line, 14%
  • 2 lines, 25%
  • 3 lines, 18%
  • ≥3 lines, 40%
Other prior treatments (% of patients)
  • Hormonal therapy, 84%†
  • bevacizumab, 40%
  • MEK inhibitor, 21%
Patient exclusion criteria
  • Candidates for debulking surgery
  • On treatment with warfarin
  • Active skin disorder requiring systemic therapy within the past year
  • Ocular disorder‡

Safety findings

Discover what you need to know about safety and adverse events.

SAFETY

Dosing information

Learn about the dosing schedule and dosing modifications for adverse events.

DOSING

*Who have received prior systemic therapy.

†As maintenance or treatment. 

‡Including a history of retinal pathology, an active or chronic visually significant corneal disorder, or a history of glaucoma.
BIRC, blinded independent review committee; DoR, duration of response; ORR, overall response rate. 

References: 1. Banerjee SN, et al. J Clin Oncol 2025;43(25):2782-2792. 2. Avmapki Fakzynja Co‑Pack. Prescribing Information. Verastem Inc; 2025. 
3. Grisham RN, et al. Oral presented at Society of Gynecologic Oncology. March 14-17, 2025; Seattle, WA.

INDICATION

Avmapki Fakzynja Co‑Pack is indicated for the treatment of adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior systemic therapy.

This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

IMPORTANT SAFETY INFORMATION

Warnings and Precautions

  • Ocular Toxicities: Ocular toxicities, including visual impairment and vitreoretinal disorders, occurred. Perform comprehensive ophthalmic evaluation at baseline, prior to cycle 2, every three cycles thereafter, and as clinically indicated. Withhold Avmapki Fakzynja Co‑Pack for ocular toxicities until improvement at the same or reduced dose. Permanently discontinue Avmapki Fakzynja Co‑Pack for any grade 4 toxicity.
  • Serious Skin Toxicities: Skin toxicities, including photosensitivity and Severe Cutaneous Adverse Reactions (SCARs), occurred. Adhere to concomitant medications. Monitor for skin toxicities and interrupt, reduce or permanently discontinue Avmapki Fakzynja Co‑Pack based on severity, tolerability and duration.
  • Hepatotoxicity: Monitor liver function tests prior to each cycle, on day 15 of the first 4 cycles, and as clinically indicated. Withhold, reduce or discontinue Avmapki Fakzynja Co‑Pack based on severity and persistence of abnormality.
  • Rhabdomyolysis: Monitor creatine phosphokinase prior to the start of each cycle, on day 15 of the first four cycles, and as clinically indicated. If increased CPK occurs, evaluate patients for rhabdomyolysis or other causes. Withhold, reduce or permanently discontinue Avmapki Fakzynja Co‑Pack based on severity and duration of the adverse reaction.
  • Embryo-Fetal Toxicity: Avmapki Fakzynja Co‑Pack can cause fetal harm. Advise patients of the potential risk to a fetus and to use effective contraception.

Adverse Reactions

  • The most common (≥ 25%) adverse reactions, including laboratory abnormalities, were increased creatine phosphokinase, nausea, fatigue, increased aspartate aminotransferase, rash, diarrhea, musculoskeletal pain, edema, decreased hemoglobin, increased alanine aminotransferase, vomiting, increased blood bilirubin, increased triglycerides, decreased lymphocyte count, abdominal pain, dyspepsia, dermatitis acneiform, vitreoretinal disorders, increased alkaline phosphatase, stomatitis, pruritus, visual impairment, decreased platelet count, constipation, dry skin, dyspnea, cough, urinary tract infection, and decreased neutrophil count.

Drug Interactions

  • Strong and moderate CYP3A4 inhibitors: Avoid concomitant use with Avmapki Fakzynja Co‑Pack.
  • Strong and moderate CYP3A4 inducers: Avoid concomitant use with Avmapki Fakzynja Co‑Pack.
  • Warfarin: Avoid concomitant use of Avmapki Fakzynja Co‑Pack with warfarin and use an alternative to warfarin.
  • Gastric acid reducing agents: Avoid concomitant use of Avmapki Fakzynja Co‑Pack with proton pump inhibitors (PPIs) or H2 receptor antagonists. If use of an acid-reducing agent cannot be avoided, administer Fakzynja 2 hours before or 2 hours after the administration of a locally acting antacid.

Use in Specific Populations

  • Lactation: Advise not to breastfeed.
  • Fertility: May impair fertility in males and females.

Click here for full Prescribing Information